Obesity linked to worse outcomes in early breast cancer treatment

Obesity is associated with worse outcomes overall in early-stage breast cancer, researchers reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

Obesity was linked to shorter time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS). The exception was treatment with endocrine therapy (mainly tamoxifen), in which obesity was associated with a protective effect.

"The findings add to the body of evidence indicating that obesity, in general, increases a patient's chance for having a worse prognosis," said lead researcher Sao Jiralerspong, M.D., Ph.D., an assistant professor of medicine at Baylor College of Medicine.

"Obesity is a probable risk factor for worse outcomes, and ours is the latest study to suggest it has an effect on treatment outcome as well," Jiralerspong said.

Using data from the Lester and Sue Smith at Baylor, Jiralerspong and colleagues examined the link between weight and treatment modality in 4,368 patients treated between 1970 and 1995.

For the group as a whole, data revealed that overweight patients had similar outcomes to normal-weight patients, but had an increased risk for worse TTR, DFS and OS.

Among patients who received no or endocrine therapy, there was a trend for worse in obese patients compared with normal-weight patients.

Obese patients who received chemotherapy fared significantly worse compared with normal-weight patients, "with the magnitude of this effect approaching that of the degree of benefit expected from chemotherapy," Jiralerspong said.

In contrast, overweight patients who received endocrine therapy, predominantly tamoxifen, fared significantly better compared with normal-weight patients.

"Finding that have a better outcome than normal-weight after tamoxifen treatment is surprising. We are examining the possible reasons for this," Jiralerspong said.

He said that obesity could contribute to worse outcomes because of biological factors associated with excess weight, such as higher blood insulin and estrogen levels, inflammation and growth factors secreted by fat cells. But Jiralerspong also added that more research is needed to understand the effect of body mass on adjuvant treatment because of the unexpected findings and because additional agents are in use today compared with the time period studied.

add to favorites email to friend print save as pdf

Related Stories

Breast cancer more aggressive among obese women

Mar 14, 2008

Women with breast cancer have more aggressive disease and lower survival rates if they are overweight or obese, according to findings published in the March 15 issue of Clinical Cancer Research, a journal of the American Associ ...

Obesity linked with poorer breast cancer outcomes

Dec 10, 2009

Breast cancer patients with a high body mass index (BMI) have a poorer cancer prognosis later in life. Specifically, their treatment effect does not last as long and their risk of death increases.

Minimizing obesity's impact on ovarian cancer survival

Dec 29, 2008

Obesity affects health in several ways, but new research shows obesity can have minimal impact on ovarian cancer survival. A study by researchers at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center ...

Recommended for you

User comments